Quantcast
Home / Columnists / Berko / BERKO: Potential HIV cure could boost company’s stock (access required)

BERKO: Potential HIV cure could boost company’s stock (access required)

DEAR MR. BERKO: It cost $22,000 last year to treat our 28-year-old son's HIV; three years earlier, his drug cocktail cost us $38,000 a year. He will take this drug cocktail every day for the rest of his life. He has no insurance; however, we have good support from our church and a medical team. ...

Leave a Reply

Your email address will not be published. Required fields are marked *

*

 

%d bloggers like this: